{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:27:20Z","timestamp":1767828440830,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801797"],"award-info":[{"award-number":["81801797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.msard.2019.04.023","type":"journal-article","created":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T09:40:03Z","timestamp":1555839603000},"page":"33-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Dan","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-430X","authenticated-orcid":false,"given":"Mianwang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.04.023_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/713519","article-title":"Interferon alpha association with neuromyelitis optica","volume":"2013","author":"Asgari","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2019.04.023_bib0002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-011-8296-5","article-title":"Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity","volume":"44","author":"Axtell","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"416","key":"10.1016\/j.msard.2019.04.023_bib0003","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"Benveniste","year":"2007","journal-title":"Sci. STKE"},{"issue":"3 Pt 1","key":"10.1016\/j.msard.2019.04.023_bib0004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.44.3_Part_1.406","article-title":". Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis","volume":"44","author":"Durelli","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.023_bib0005","first-page":"118","article-title":"Chronic hepatitis C infection associated with neuromyelitis optica and antinuclear antibodies","volume":"58","author":"Earnest","year":"2010","journal-title":"J. Assoc. Phys. India"},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.04.023_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2011.09.032","article-title":"Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis","volume":"313","author":"Feng","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"6\u20137","key":"10.1016\/j.msard.2019.04.023_bib0007","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","article-title":"Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use","volume":"89","author":"Ferrantini","year":"2007","journal-title":"Biochimie"},{"issue":"17","key":"10.1016\/j.msard.2019.04.023_bib0008","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2174\/138161208784746824","article-title":"HCV and autoimmunity","volume":"14","author":"Ferri","year":"2008","journal-title":"Curr. Pharm. Des."},{"issue":"Pt 12","key":"10.1016\/j.msard.2019.04.023_bib0009","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/brain\/awr262","article-title":"Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity","volume":"134","author":"Guerau-de-Arellano","year":"2011","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.msard.2019.04.023_bib0010","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/1352458507078684","article-title":"Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection","volume":"13","author":"Hoftberger","year":"2007","journal-title":"Multiple Scler."},{"issue":"4","key":"10.1016\/j.msard.2019.04.023_bib0011","first-page":"1303","article-title":"Dry cough and optic neuritis: two rare complications of interferon alpha treatment in chronic viral hepatitis","volume":"96","author":"Isler","year":"2001","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.msard.2019.04.023_bib0012","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.10090","article-title":"Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia","volume":"70","author":"Kataoka","year":"2002","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.msard.2019.04.023_bib0013","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.expneurol.2013.02.005","article-title":"Neuromyelitis optica-like pathology is dependent on type I interferon response","volume":"247","author":"Khorooshi","year":"2013","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2019.04.023_bib0014","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Multiple Scler."},{"issue":"17","key":"10.1016\/j.msard.2019.04.023_bib0015","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2169\/internalmedicine.51.7590","article-title":"Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity","volume":"51","author":"Kitada","year":"2012","journal-title":"Intern. Med."},{"issue":"Pt 7","key":"10.1016\/j.msard.2019.04.023_bib0016","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2019.04.023_bib0017","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0168-8278(05)80331-9","article-title":"Optic tract neuropathy complicating low-dose interferon treatment","volume":"21","author":"Manesis","year":"1994","journal-title":"J. Hepatol."},{"key":"10.1016\/j.msard.2019.04.023_bib0018","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/2050-6511-15-56","article-title":"A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon alpha","volume":"15","author":"Mangioni","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.msard.2019.04.023_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1076\/ocii.10.4.299.15588","article-title":"Multiple sclerosis-like disease secondary to alpha interferon","volume":"10","author":"Matsuo","year":"2002","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.msard.2019.04.023_bib0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1212\/WNL.52.5.1049","article-title":"Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian study group on interferon-alpha in multiple sclerosis","volume":"52","author":"Myhr","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.023_bib0021","first-page":"369","article-title":"Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis","volume":"3","author":"Paolicelli","year":"2009","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.msard.2019.04.023_bib0022","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00415-013-7202-x","article-title":"Fulminant myelitis with NMO IgG antibody following treatment with interferon alpha","volume":"261","author":"Usmani","year":"2014","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2019.04.023_bib0023","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.04.023_bib0024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2019.04.023_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2019.04.023_bib0026","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2019.04.023_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5692\/clinicalneurol.52.19","article-title":"[Case of NMO (neuromyelitis optica) spectum disorder triggered by interferon alpha, which involved extensive pyramidal tract lesion of the brain]","volume":"52","author":"Yamasaki","year":"2012","journal-title":"Rinsho Shinkeigaku"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930183X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930183X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:43Z","timestamp":1761900283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481930183X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"alternative-id":["S221103481930183X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.04.023","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}